Literature DB >> 15973673

Late thrombosis following treatment of in-stent restenosis with drug-eluting stents after discontinuation of antiplatelet therapy.

Richard E Waters1, David E Kandzari, Harry R Phillips, Lawrence E Crawford, Michael H Sketch.   

Abstract

Drug-eluting stent usage has become commonplace for the percutaneous treatment of de novo coronary lesions, but the safety and efficacy profile for their evolving usage in restenotic lesions is largely unknown. We report three cases of angiographically confirmed drug-eluting stent thrombosis following treatment of restenotic lesions that occurred late (193, 237, and 535 days) and shortly after interruption of antiplatelet therapy. All three patients suffered ST elevation myocardial infarction, and there was one death. Further studies are necessary to better define the associated risk and ideal duration of antiplatelet therapy necessary in this cohort of patients with restenotic lesions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15973673     DOI: 10.1002/ccd.20428

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  4 in total

Review 1.  Drug eluting stents for ST-elevation myocardial infarction: risk and benefit.

Authors:  Jason Ryan; Donald E Cutlip; David J Cohen; Duane S Pinto
Journal:  J Thromb Thrombolysis       Date:  2007-05-05       Impact factor: 2.300

2.  Drug-eluting stents not for all patients.

Authors:  F H de Man; P R Stella; P A Doevendans
Journal:  Neth Heart J       Date:  2006-05       Impact factor: 2.380

Review 3.  Drug-eluting stent thrombosis 1,659 days after stent deployment: case report and literature review.

Authors:  Anthony Al-Dehneh; Hartaj Virk; Yazan Alkhouri; Aiman Hamdan; Mahesh Bikkina
Journal:  Tex Heart Inst J       Date:  2010

Review 4.  Is late stent thrombosis in drug-eluting stents a real clinical issue? A single-center experience and review of the literature.

Authors:  J Carlsson; B von Wagenheim; R Linder; T M Anwari; J Qvist; I Petersson; T Magounakis; B Lagerqvist
Journal:  Clin Res Cardiol       Date:  2006-12-22       Impact factor: 5.460

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.